Mirati draws Hold rating at Needham despite recent selloff

Dec. 14, 2022 3:36 PM ETMirati Therapeutics, Inc. (MRTX)AMGNBy: Dulan Lokuwithana, SA News Editor1 Comment

Business on Wall Street in Manhattan

Pgiam/iStock via Getty Images

Needham initiated coverage on cancer-focused biotech Mirati Therapeutics (NASDAQ:MRTX) on Wednesday with a Hold recommendation citing uncertainty over near-term upside despite the recent selloff in company shares.

Mirati (MRTX) shares sold off last week

Recommended For You

Comments (1)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.